IQ EQ FUND MANAGEMENT IRELAND Ltd Has $1.40 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,390 shares of the company’s stock after purchasing an additional 84 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in IDEXX Laboratories were worth $1,402,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Insight Wealth Strategies LLC lifted its holdings in IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after buying an additional 7,041 shares during the period. Geode Capital Management LLC grew its holdings in IDEXX Laboratories by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company’s stock worth $1,138,732,000 after acquiring an additional 40,349 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $1,263,000. Sax Wealth Advisors LLC lifted its stake in shares of IDEXX Laboratories by 76.3% in the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock valued at $590,000 after purchasing an additional 617 shares during the period. Finally, Hantz Financial Services Inc. boosted its position in shares of IDEXX Laboratories by 11.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock valued at $3,199,000 after purchasing an additional 800 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Up 1.2 %

IDXX opened at $422.54 on Friday. The firm has a market capitalization of $34.25 billion, a PE ratio of 39.60, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The company’s 50-day moving average is $437.13 and its 200 day moving average is $443.72.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective on the stock. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.